ACAD Stock Analysis: Buy, Sell, or Hold?
ACAD - Acadia Pharmaceuticals Inc.
$21.27
0.18 (0.83%)
▲
5d:
-2.0%
30d:
-3.73%
90d:
-0.58%
HOLD
MODERATE Confidence
Analysis Updated: Jun 15, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Smart Money Accumulation
None View Scanner →
Strength: 5.1/10
Get Alerted When ACAD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ACAD shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ACAD shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$43.47
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$26.99
21.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ACAD is currently trading at $21.27, which is considered fair relative to its 30-day fair value range of $21.01 to $21.88. From a valuation perspective, the stock is trading at a discount (Forward PE: 23.8) compared to its historical average (27.3). Remarkably, the market is currently pricing in an annual earnings decline of 4.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ACAD is in a downtrend. The price is currently testing key support at $20.75. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ACAD has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $31.65 (+48.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ACAD is in a downtrend. The price is currently testing key support at $20.75. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ACAD has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $31.65 (+48.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$21.01 -
$21.88
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
59.6%
Protect Your Profits
Holding ACAD? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 48.8% below Wall St target ($31.65)
Trading Range Analysis
30-Day Trading Range
$21.01 -
$21.88
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.82
(3.8%)
Support & Resistance Levels
Support Level
$20.75
Resistance Level
$22.15
Current Trend
Downtrend
Technical data as of
Jun 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
23.81
Wall Street Target
$31.65
(+48.8%)
Revenue Growth (YoY)
9.7%
Earnings Growth (YoY)
-81.8%
Profit Margin
34.3%
Valuation Discount vs History
-4.4% cheaper
PE vs Historical
23.8 vs 27.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.4%
(market-implied from PE analysis)
1-Year Target
$20.33
(-4%)
2-Year Target
$19.43
(-9%)
3-Year Target
$18.58
(-13%)
3-Yr Target (if PE normalizes)
(PE: 24→27)
$21.30
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 23.8, Growth: 124.8%)
$71.77
(+238%)
Base:
(SPY PE: 21.8, Growth: 124.8%)
$65.64
(+209%)
Bear:
(PE: 18.5, Growth: 124.8%)
$55.80
(+162%)
📈
Valuation based on Current Earnings
Trailing PE: 9.54 | Current EPS (TTM): $2.21
Bull Case
$11.60
(-46%)
Analyst growth -50.0%, PE expands to 10.5
Base Case
$10.55
(-50%)
Market implied -50.0%, PE stable at 9.5
Bear Case
$14.34
(-33%)
Severe decline -20.0%, PE contracts to 8.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 23.8 to 27.3
Stabilization Target:
$24.38
(+14.6%)
PE Expansion Potential:
+14.6%
Share & Embed Analysis
Last updated: June 16, 2026 9:18 AM ET
Data refreshes hourly during market hours. Next update: 10:18 AM
Data refreshes hourly during market hours. Next update: 10:18 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACAD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
James Kihara
SELL
1030 shares
2026-04-07
Mark C Schneyer
SELL
2709 shares
2026-04-07
Jennifer J Rhodes
SELL
6950 shares
2026-02-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 63 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$102 | 58 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 61 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 55 HOLD |
Advanced ACAD Option Strategies
Professional options setups generated by AI based on today's ACAD price and gamma walls.
